Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

Citation(s) in RCA

1
(from Reference Citation Analysis)

Indexed Articles

Ranked By

Results Analysis

Year Published Analysis
Article Type Analysis
Journal Title Analysis
Category Analysis

Results Analysis

Year Published

Show more Refine

Article Statistics

Refine

Publication Titles

Show more Refine

Category

Show more Refine

For: Yohannan B, Sridhar A, Nguyen N, Rios A. Durable remission with Bruton's tyrosine kinase inhibitor therapy in a patient with leptomeningeal disease secondary to relapsed mantle cell lymphoma. BMJ Case Rep 2022;15:e249631. [PMID: 35732356 PMCID: PMC9226949 DOI: 10.1136/bcr-2022-249631] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/25/2022] [Indexed: 01/01/2023] Open

For:	Yohannan B, Sridhar A, Nguyen N, Rios A. Durable remission with Bruton's tyrosine kinase inhibitor therapy in a patient with leptomeningeal disease secondary to relapsed mantle cell lymphoma. BMJ Case Rep 2022;15:e249631. [PMID: 35732356 PMCID: PMC9226949 DOI: 10.1136/bcr-2022-249631] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/25/2022] [Indexed: 01/01/2023] Open

Number

Cited by Other Article(s)

Barrett A, Eyre TA, Bhuva S, Aljurf M, Fakih RE, Ashshi MA, Alshaibani A. Complete response of mantle cell lymphoma with central nervous system involvement at diagnosis with acalabrutinib - Case report. EJHAEM 2024;5:238-241. [PMID: 38406527 PMCID: PMC10887248 DOI: 10.1002/jha2.830] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 09/13/2023] [Revised: 10/30/2023] [Accepted: 11/07/2023] [Indexed: 02/27/2024]